Investigation of blood perfusion and metabolic activity of brain tumours in adults by using 99mTc-methoxyisobutylisonitrile

Nuclear Medicine Communications

Volumn 31, Issue 11, 2010, Pages 962-973

  Petrovic, Nebojsa S ^a   Grujicic, Danica ^a   Artiko, Vera M ^a   Sobic Saranovic, Dragana P ^a   Gajic, Milan M ^b   Jaksic, Emilija ^a   Grajic, Mirko M ^a   Antonovic, Olga J ^a   Petrovic, Milorad N ^a   Obradovic, Vladimir B ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

brain tumour; radionuclide cerebral angiography; single photon emission tomography

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADOLESCENT; ADULT; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN METASTASIS; BRAIN REGION; BRAIN TISSUE; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG RETENTION; DRUG UPTAKE; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; INTRACRANIAL TUMOR; LYMPHOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; MENINGIOMA; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SINGLE PHOTON EMISSION TOMOGRAPHY; TISSUE METABOLISM; TISSUE PERFUSION; TOMOGRAPHY; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; BIOLOGICAL TRANSPORT; BRAIN NEOPLASMS; CEREBRAL ANGIOGRAPHY; CEREBROVASCULAR CIRCULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 77958000385     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32833ea6cc     Document Type: Article

References (69)

1. Louis DN, Ohgaki H,Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114:97-109.
2. Al-Okaili RN, Krejza J, Woo JH, Wolf RL, O'Rourke DM, Judy KD, et al. Intraaxial brain masses: MR imaging-based diagnostic strategy - initial experience. Radiology 2007; 243:539-550.
3. Herholz K, Coope D, Jackson A. Metabolic and molecular imaging in neuro-oncology. Lancet Neurol 2007; 6:711-724.
4. Giordana MT, Cordera S, Boghi A. Cerebral metastases as first symptom of cancer: a clinico-pathologic study. J Neurooncol 2000; 50:265-273.
5. Martin-Villalba A, Okuducu AF, von Deimling A. The evolution of our understanding on glioma. Brain Pathology 2008; 18:455-463.
6. Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J. Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol 2003; 129:477-484.
7. Galldiks N, Kracht LW, Burghaus L, Ullrich RT, Backes H, Brunn A, et al. Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging 2010; 9:40-46.
8. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007; 67:3560-3564.
9. Ozduman K,Wollmann G, Piepmeier JM, van den Pol AN. Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain. J Neurosci 2008; 28:1882-1893.
10. Del Sole A, Falini A, Ravasi L, Ottobrini L, De Marchis D, Bombardieri E, et al. Anatomical and biochemical investigation of primary brain tumours. Eur J Nucl Med Mol Imaging 2001; 28:1851-1872.
11. Kirton A, Kloiber R, Rigel J, Wolff J. Evaluation of pediatric CNS malignancies with 99mTc-methoxyisobutylisonitrile SPECT. J Nucl Med 2002; 43:1438-1443.
12. Del Sole A, Moncayo R, Tafuni G, Lucignani G. Position of nuclear medicine techniques in the diagnostic work-up of brain tumours. Q J Nucl Med Mol Imaging 2004; 48:76-81.
13. Shaw EG, Wisoff JH. Prospective clinical trials of intracranial low-grade glioma in adults and children. Neuro Oncol 2003; 5:153-160.
14. Spampinato MV, Smith JK, Kwock L, Ewend M, Grimme JD, Camacho DL, et al. Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 2007; 188:204-212.
15. O'Tuama LA, Treves ST, Larar JN, Packard AB, Kwan AJ, Barnes PD, et al. Thallium-201 versus technetium-99m-MIBI SPECT in evaluation of childhood brain tumors: a within-subject comparison. J Nucl Med 1993; 34:1045-1051.
16. Bagni B, Pinna L, Tamarozzi R, Cattaruzzi E, Marzola MC, Bagni I, et al. SPET imaging of intracranial tumours with 99mTc-sestamibi. Nucl Med Commun 1995; 16:258-264.
17. Sobic-Saranovic DP, Pavlovic SV, Jovanovic IV, Stefanovic ID, Artiko VM, Djukic MM, et al. Evaluation of myocardial perfusion and function by gated single-photon emission computed tomography technetium-99m methoxyisobutylisonitrile in children and adolescents with severe congenital heart disease. Nucl Med Commun 2010; 31:12-21.
18. Ak I, Gulbas Z, Altinel F, Vardareli E. Tc-99m MIBI uptake and its relation to the proliferative potential of brain tumors. Clin Nucl Med 2003; 28:29-33.
19. Moretti JL, Hauet N, Caglar M, Rebillard O, Burak Z. To use MIBI or not to use MIBI? That is the question when assessing tumour cells. Eur J Nucl Med Mol Imaging 2005; 32:836-842.
20. De La Peña RC, Ketonen L, Villanueva-Mayer J. Imaging of brain tumours in AIDS patients by means of dual-isotope thallium-201 and technetium- 99m sestamibi single-photon emission tomography. Eur J Nucl Med 1998; 25:1404-1411.
21. Yamamoto Y, Nishiyama Y, Toyama Y, Kunishio K, Satoh K, Ohkawa M. 99mTc-MIBI and 201Tl SPECT in the detection of recurrent brain tumours after radiation therapy. Nucl Med Commun 2002; 23:1183-1190.
22. Aronen HJ, Pardo FS, Kennedy DN, Belliveau JW, Packard SD, Hsu DW, et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000; 6:2189-2200.
23. Sygitowicz M, Lass P, Lyczak P, Stepieñ-Koć miel E, Taraszewska M, Bandurski T. Tc-99m-MIBI and Tc-99m-HMPAO accumulation in primary and metastatic brain tumors assessed by brain SPECT. Neurol Neurochir Pol 1998; 32:1099-1106.
24. Hakyemez B, Erdogan C, Bolca N, Yildirim N, Gokalp G, Parlak M. Evaluation of different cerebral mass lesions by perfusion-weighted MR imaging. J Magn Reson Imaging 2006; 24:817-824.
25. Schwartz RB, Holman BL, Polak JF, Garada BM, Schwartz MS, Folkerth R, et al. Dual-isotope single-photon emission computerized tomography scanning in patients with glioblastoma multiforme: association with patient survival and histopathological characteristics of tumor after high-dose radiotherapy. J Neurosurg 1998; 89:60-68.
26. Bleichner-Perez S, Le Jeune F, Dubois F, Steinling M. 99mTc-MIBI brain SPECT as an indicator of the chemotherapy response of recurrent, primary brain tumors. Nucl Med Commun 2007; 28:888-894.
27. Front D. Scintigraphic assessment of vascularity and blood-tissue barrier of human brain tumours. J Neurol Neurosurg Psychiatry 1978; 41:18-23.
28. Benard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Semin Nucl Med 2003; 33:148-162.
29. Murase K, Fujioka H, Inoue T, Ishimaru Y, Akamune A, Yamamoto Y, et al. Reproducibility of the brain perfusion index for measuring cerebral blood flow using technetium-99m compounds. Eur J Nucl Med Mol Imaging 2001; 28:1640-1646.
30. Takasawa M, Murase K, Oku N, Kawamata M, Imaizumi M, Yoshikawa T, et al. Automatic determination of brain perfusion index for measurement of cerebral blood flow using spectral analysis and 99mTc-HMPAO. Eur J Nucl Med Mol Imaging 2002; 29:1443-1446.
31. Hakyemez B, Erdogan C, Ercan I, Ergin N, Uysal S, Atahan S. High-grade and low-grade gliomas: differentiation by using perfusion MR imaging. Clin Radiol 2005; 60:493-502.
32. Le Jeune FP, Dubois F, Blond S, Steinling M. Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies. J Neurooncol 2006; 77:177-183.
33. Kunishio K, Okada M, Matsumoto Y, Nagao S, Nishiyama Y. Technetium-99m sestamibi single photon emission computed tomography findings correlated with P-glycoprotein expression in pituitary adenoma. J Med Invest 2006; 53:285-291.
34. Jain R, Ellika SK, Scarpace L, Schultz LR, Rock JP, Gutierrez J, et al. Quantitative estimation of permeability surface-area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade. AJNR Am J Neuroradiol 2008; 29:694-700.
35. Mineura K, Shioya H, Kowada M, Ogawa T, Hatazawa J, Uemura K. Blood flow and metabolism of oligodendrogliomas: a positron emission tomography study with kinetic analysis of 18F-fluorodeoxyglucose. J Neurooncol 1999; 43:49-57.
36. Rubinstein R, Karger H, Pietrzyk U, Siegal T, Gomori JM, Chisin R. Use of 201Thallium brain SPECT, image registration, and semi-quantitative analysis in the follow-up of brain tumors. Eur J Radiol 1996; 21:188-195.
37. O'Tuama LA, Janicek MJ, Barnes PD, Scott RM, Black PM, Sallan SE, et al. 201Tl/99mTc-HMPAO SPECT imaging of treated childhood brain tumors. Pediatr Neurol 1991; 7:249-257.
38. Sugahara T, Korogi Y, Kochi M, Ikushima I, Hirai T, Okuda T, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998; 171:1479-1486.
39. Hakyemez B, Yildirim N, Erdoqan C, Kocaeli H, Korfali E, Parlak M. Meningiomas with conventional MRI findings resembling intraaxial tumors: can perfusion-weighted MRI be helpful in differentiation? Neuroradiology 2006; 48:695-702.
40. Yang S, Law M, Zagzag D, Wu HH, Cha S, Golfinos JG, et al. Dynamic contrast-enhanced perfusion MR imaging measurements of endothelial permeability: differentiation between atypical and typical meningiomas. AJNR Am J Neuroradiol 2003; 24:1554-1559. (Pubitemid 37151719)
41. Alexiou GA, Vartholomatos G, Tsiouris S, Papadopoulos A, Kyritsis AP, Polyzoidis KS, et al. Evaluation of meningioma aggressiveness by 99mTc-Tetrofosmin SPECT. Clin Neurol Neurosurg 2008; 110:645-648.
42. Nishiyama Y, Yamamoto Y, Fukunaga K, Satoh K, Kunishio K, Ohkawa M. Comparison of 99mTc-MIBI with 201Tl chloride SPET in patients with malignant brain tumours. Nucl Med Commun 2001; 22:631-639.
43. Staudenherz A, Fazeny B, Marosi C, Nasel C, Hoffmann M, Puig S, et al. Does 99mTc-Sestamibi in high-grade malignant brain tumors reflect bloodbrain barrier damage only? Neuroimage 2000; 12:109-111.
44. Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18- fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998; 39:778-785.
45. Matheja P, Rickert C,Weckesser M, Palkovic S, Löttgen J, Riemann B, et al. Sequential scintigraphic strategy for the differentiation of brain tumours. Eur J Nucl Med Mol Imaging 2000; 27:550-558.
46. Lupo JM, Cha S, Chang SM, Nelson SJ. Analysis of metabolic indices in regions of abnormal perfusion in patients with high-grade glioma. AJNR Am J Neuroradiol 2007; 28:1455-1461.
47. Meyer PT, Schreckenberg M, Spetzger U, Meyer GF, Sabri O, Setani KS, et al. Comparison of visual and ROI-based brain tumour grading using 18F-FDG PET: ROC analyses. Eur J Nucl Med Mol Imaging 2001; 28:165-174.
48. Yokogami K, Kawano H, Moriyama T, Uehara H, Sameshima T, Oku T, et al. Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET? Eur J Nucl Med 1998; 25:401-409.
49. Shibata Y, Yamamoto T, Takano S, Katayama W, Takeda T, Matsumura A. Direct comparison of thallium-201 and technetium-99m MIBI SPECT of a glioma by receiver operating characteristic analysis. J Clin Neurosci 2009; 16:264-269.
50. Sasajima T, Shimada N, Naitoh Y, Takahashi M, Hu Y, Satoh T, et al. 99mTc-MIBI imaging for prediction of therapeutic effects of secondgeneration MDR1 inhibitors in malignant brain tumors. Int J Cancer 2007; 121:2637-2645. (Pubitemid 350136406)
51. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Charlop AW, et al. [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow. Nucl Med Biol 2002; 29:719-727.
52. Baldari S, Restifo PG, Cosentino S, Minutoli F. Investigation of brain tumours with 99mTc-MIBI SPET. Q J Nucl Med 2002; 46:336-345.
53. Soler C, Beauchesne P, Maatougui K, Schmitt T, Barral FG, Michel D, et al. Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy. Eur J Nucl Med 1998; 25:1649-1657.
54. Maffioli L, Gasparini M, Chiti A, Gramaglia A, Mongoj V, Pozzi A, et al. Clinical role of technetium-99m sestamibi single-photon emission tomography in evaluating pretreated patients with brain tumours. Eur J Nucl Med 1996; 23:308-311.
55. Gumprecht H, Grosu AL, Souvatsoglou M, Dzewas B, Weber WA, Lumenta CB. 11C-Methionine positron emission tomography for preoperative evaluation of suggestive low-grade gliomas. Zentralbl Neurochir 2007; 68:19-23.
56. Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J, Nikolic N. Clinical prognostic factors in patients with malignant glioma treated with combined modality approach. Am J Clin Oncol 2004; 27:195-204.
57. Beauchesne P, Soler C. Correlation of 99mTc-MIBI brain SPECT (functional index ratios) and survival after treatment failure in malignant glioma patients. Anticancer Res 2002; 22:3081-3085.
58. Beauchesne P, Pedeux R, Boniol M, Soler C. 99mTc-sestamibi brain SPECT after chemoradiotherapy is prognostic of survival in patients with high-grade glioma. J Nucl Med 2004; 45:409-413.
59. Palumbo B, Lupattelli M, Pelliccioli GP, Chiarini P, Moschini TO, Palumbo I, et al. Association of 99mTc-MIBI brain SPECT and proton magnetic resonance spectroscopy (1H-MRS) to assess glioma recurrence after radiotherapy. Q J Nucl Med Mol Imaging 2006; 50:88-93.
60. Van Laere K, Dumont F, Koole M, Dierckx R. Non-invasive methods for absolute cerebral blood flow measurement using 99mTc-ECD: a study in healthy volunteers. Eur J Nucl Med Mol Imaging 2001; 28:862-872.
61. Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. J Neurooncol 2000; 50:99-108.
62. Ohtani T, Kurihara H, Ishiuchi S, Saito N, Oriuchi N, Inoue T, et al. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med 2001; 28:1664-1670.
63. Cecchin D, Chondrogiannis S, Puppa AD, Rotilio A, Zustovich F, Manara R, et al. Presurgical 99mTc-sestamibi brain SPET/CT versus SPET: a comparison with MRI and histological data in 33 patients with brain tumours. Nucl Med Commun 2009; 30:660-668.
64. Filippi L, Schillaci O, Santoni R, Manni C, Danieli R, Simonetti G. Usefulness of SPECT/CT with a hybrid camera for the functional anatomical mapping of primary brain tumors by [Tc99m] tetrofosmin. Cancer Biother Radiopharm 2006; 21:41-48.
65. Henze M, Mohammed A, Schlemmer H, Herfarth KK, Mier W, Eisenhut M, et al. Detection of tumour progression in the follow-up of irradiated low-grade astrocytomas: comparison of 3-[123I]iodo-alpha-methyl-L-tyrosine and 99mTc-MIBI SPECT. Eur J Nucl Med Mol Imaging 2002; 29:1455-1461.
66. Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ, et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000; 27:542-549.
67. Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008; 49:694-699.
68. Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, et al. 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 2008; 35:2009-2017.
69. Barwick T, Bencherif B, Mountz JM, Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun 2009; 30:908-917.